NASDAQ:HZNP - Horizon Therapeutics Public Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $119.89
Forecasted Upside: 6.32 %
Number of Analysts: 10
Breakdown:
1 Sell Ratings
1 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$112.76 As of 10/19/2021 04:10 PM ET

▼ -0.19 (-0.17%)

1 month | 3 months | 12 months

Get New Horizon Therapeutics Public Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for HZNP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HZNP

^$119.89

▲ +6.32% Upside Potential

This price target is based on 10 analysts offering 12 month price targets for Horizon Therapeutics Public in the last 3 months. The average price target is $119.89, with a high forecast of $135.00 and a low forecast of $100.00. The average price target represents a 6.32% upside from the last price of $112.76.

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Horizon Therapeutics Public. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/27/2020

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/26/2020

0 strong buy ratings
11 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

10/24/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/22/2021

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/22/2021

0 strong buy ratings
10 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

7/21/2021

0 strong buy ratings
8 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

9/19/2021

0 strong buy ratings
8 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

10/19/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
10/13/2021	Jefferies Financial Group	Initiated Coverage	Buy	$132.00	Low
8/26/2021	Morgan Stanley	Boost Price Target	Overweight	$103.00 ➝ $135.00	Low
8/24/2021	The Goldman Sachs Group	Boost Price Target	Neutral	$96.00 ➝ $107.00	Low
8/5/2021	BMO Capital Markets	Boost Price Target	Outperform	$118.00 ➝ $132.00	Low
8/5/2021	Citigroup	Boost Price Target	Buy	$117.00 ➝ $121.00	Medium
5/27/2021	Maxim Group	Reiterated Rating	Reduce		High
3/29/2021	Morgan Stanley	Reiterated Rating	Overweight	$103.00	High
3/25/2021	Guggenheim	Boost Price Target	Buy	$115.00 ➝ $120.00	Low
3/22/2021	Morgan Stanley	Initiated Coverage	Overweight	$103.00	Medium
3/19/2021	Jefferies Financial Group	Reiterated Rating	Buy	$120.00	Low
3/18/2021	Citigroup	Boost Price Target		$116.00 ➝ $120.00	High
3/17/2021	Stifel Nicolaus	Boost Price Target	Buy	$110.00 ➝ $125.00	High
3/11/2021	Wolfe Research	Initiated Coverage	Outperform	$107.00	Low
2/17/2021	Jefferies Financial Group	Boost Price Target		$103.00 ➝ $120.00	Low
2/9/2021	Bank of America	Reiterated Rating	Buy	$100.00	Low
11/3/2020	BMO Capital Markets	Boost Price Target	Outperform	$105.00 ➝ $110.00	Medium
9/9/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$110.00	High
8/27/2020	Citigroup	Initiated Coverage	Buy	$112.00	Medium
8/17/2020	Bank of America	Boost Price Target	Buy	$92.00 ➝ $95.00	Low
8/10/2020	Morgan Stanley	Boost Price Target	Overweight	$70.00 ➝ $90.00	Low
8/6/2020	Guggenheim	Boost Price Target		$64.00 ➝ $100.00	High
8/6/2020	BMO Capital Markets	Boost Price Target	Outperform	$70.00 ➝ $105.00	High
8/3/2020	Stifel Nicolaus	Boost Price Target		$60.00 ➝ $85.00	Low
7/31/2020	Morgan Stanley	Boost Price Target	Overweight	$50.00 ➝ $70.00	Low
7/22/2020	Piper Sandler	Boost Price Target	Overweight	$61.00 ➝ $90.00	Low
7/16/2020	Guggenheim	Boost Price Target		$50.00 ➝ $64.00	Low
6/5/2020	Piper Sandler	Reiterated Rating	Buy	$61.00	Medium
5/29/2020	Stifel Nicolaus	Boost Price Target		$50.00 ➝ $60.00	High
5/26/2020	Bank of America	Boost Price Target	Buy	$52.00 ➝ $57.00	Medium
5/21/2020	Piper Sandler	Boost Price Target	Overweight	$50.00 ➝ $61.00	Medium
5/8/2020	Morgan Stanley	Boost Price Target	Overweight	$39.00 ➝ $50.00	High
4/28/2020	Jefferies Financial Group	Boost Price Target	Buy	$47.00 ➝ $51.00	High
4/14/2020	Piper Sandler	Lower Price Target	Overweight	$46.00 ➝ $44.00	High
4/8/2020	Stifel Nicolaus	Reiterated Rating	Buy	$45.00	Low
4/2/2020	Morgan Stanley	Lower Price Target	Overweight	$42.00 ➝ $39.00	High
3/23/2020	Bank of America	Lower Price Target	Buy	$45.00 ➝ $42.00	Low
2/25/2020	Bank of America	Reiterated Rating	Buy	$45.00	High
1/22/2020	BMO Capital Markets	Boost Price Target	Outperform	$40.00 ➝ $46.00	Low
1/14/2020	JMP Securities	Boost Price Target	Outperform	$47.00	Medium
1/8/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$35.00	Low
12/24/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$36.00 ➝ $49.00	Low
12/16/2019	Morgan Stanley	Boost Price Target	Overweight	$32.00 ➝ $38.00	High
12/16/2019	Jefferies Financial Group	Boost Price Target	Buy	$35.00 ➝ $40.00	High
12/16/2019	Stifel Nicolaus	Boost Price Target	Buy	$35.00 ➝ $40.00	High
12/16/2019	BMO Capital Markets	Boost Price Target	Outperform	$36.00 ➝ $40.00	High
11/8/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$32.00 ➝ $36.00	Low
9/26/2019	Bank of America	Initiated Coverage	Buy	$34.00	High
9/13/2019	Stifel Nicolaus	Set Price Target	Buy	$35.00	Low
9/12/2019	Guggenheim	Initiated Coverage	Buy	$36.00	Low
8/26/2019	Piper Jaffray Companies	Set Price Target	Buy	$33.00	Low
8/14/2019	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$29.00 ➝ $36.00	Low
8/7/2019	Cowen	Set Price Target	Buy	$35.00	Medium
5/8/2019	Mizuho	Set Price Target	Hold	$27.00	Low
5/1/2019	Citigroup	Upgrade	Neutral ➝ Buy	$21.00 ➝ $32.00	Medium
4/4/2019	Piper Jaffray Companies	Set Price Target	Buy	$33.00	Low
4/4/2019	BMO Capital Markets	Boost Price Target	Market Perform	$29.00	Medium
4/2/2019	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Buy	$26.00 ➝ $32.00	Medium
3/8/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$32.00	Low
3/1/2019	JMP Securities	Boost Price Target	Outperform	$26.00 ➝ $38.00	High
3/1/2019	Jefferies Financial Group	Boost Price Target	Positive ➝ Buy	$34.00	High
3/1/2019	Mizuho	Reiterated Rating	Positive ➝ Neutral	$27.00	High
2/28/2019	Cowen	Set Price Target	Buy	$33.00	Medium
2/7/2019	Mizuho	Reiterated Rating	Hold	$21.00	Low
1/14/2019	Piper Jaffray Companies	Set Price Target	Buy	$26.00	Low
11/15/2018	Mizuho	Downgrade	Buy ➝ Neutral	$25.00 ➝ $21.00	High
11/7/2018	Mizuho	Reiterated Rating	Buy	$25.00	High
11/1/2018	Stifel Nicolaus	Boost Price Target	Buy	$25.00 ➝ $35.00	High
10/23/2018	Cowen	Set Price Target	Buy	$25.00	High
10/18/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$21.00	Low
10/16/2018	Mizuho	Reiterated Rating	Buy		High
10/6/2018	JMP Securities	Set Price Target	Buy	$22.00	High
10/4/2018	The Goldman Sachs Group	Set Price Target	Buy	$26.00	Low
9/24/2018	Piper Jaffray Companies	Set Price Target	Buy	$25.00	Medium
9/17/2018	Piper Jaffray Companies	Set Price Target	Buy	$25.00	High
9/13/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$21.00	Low
8/17/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$16.00 ➝ $24.00	Low
8/9/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $23.00	High
8/9/2018	Cowen	Reiterated Rating	Buy	$25.00	High
8/9/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$25.00	High
8/8/2018	Mizuho	Reiterated Rating	Buy	$18.00	High
8/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$21.00	Low
8/6/2018	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$18.00 ➝ $18.00	Low
7/25/2018	Cantor Fitzgerald	Boost Price Target	Overweight	$21.00	High
6/27/2018	Citigroup	Downgrade	Buy ➝ Neutral		Low
6/18/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00	Low
5/9/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	High
5/7/2018	Mizuho	Reiterated Rating	Buy	$18.00	Low
4/15/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	High
3/14/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	Low
3/2/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $16.00	High
3/1/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$22.00	High
3/1/2018	Cowen	Reiterated Rating	Buy	$24.00	High
3/1/2018	UBS Group	Set Price Target	Buy	$20.00	Medium
2/28/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Medium
1/12/2018	Mizuho	Upgrade	Neutral ➝ Buy	$12.00 ➝ $18.00	Medium
1/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Medium
12/27/2017	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Low
12/1/2017	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Low
11/30/2017	UBS Group	Set Price Target	Buy	$16.00 ➝ $20.00	High
11/7/2017	Jefferies Financial Group	Boost Price Target	Buy	$16.00 ➝ $21.00	N/A
10/22/2017	Stifel Nicolaus	Reiterated Rating	Buy	$20.00	N/A
10/15/2017	Piper Jaffray Companies	Set Price Target	Buy	$18.00	N/A
10/5/2017	Jefferies Financial Group	Reiterated Rating	Buy	$16.00	N/A
9/28/2017	Cowen	Reiterated Rating	Buy		Low
9/28/2017	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$16.00	Medium
9/27/2017	Jefferies Financial Group	Reiterated Rating	Buy	$16.00	Medium
9/26/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	Low
9/11/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	High
9/10/2017	Piper Jaffray Companies	Set Price Target	Buy	$18.00	Low
8/28/2017	Mizuho	Reiterated Rating	Hold	$9.00 ➝ $12.00	Medium
8/17/2017	Cantor Fitzgerald	Set Price Target	Buy	$17.00	Medium
8/10/2017	BMO Capital Markets	Reiterated Rating	Outperform	$17.00 ➝ $18.00	High
8/9/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$13.00 ➝ $17.00	High
8/9/2017	Mizuho	Reiterated Rating	Neutral	$10.00 ➝ $9.00	Low
8/8/2017	UBS Group	Set Price Target	Buy	$16.00	High
8/7/2017	Piper Jaffray Companies	Set Price Target	Buy	$18.00	High
7/31/2017	Cantor Fitzgerald	Set Price Target	Buy	$13.00	High
7/28/2017	BMO Capital Markets	Reiterated Rating	Buy	$17.00	High
7/25/2017	Piper Jaffray Companies	Set Price Target	Buy	$17.00	High
7/14/2017	Jefferies Financial Group	Reiterated Rating	Buy	$14.00	Low
6/16/2017	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$13.00	Low
6/7/2017	UBS Group	Set Price Target	Buy	$22.00 ➝ $16.00	N/A
5/9/2017	Citigroup	Lower Price Target	Buy	$20.00 ➝ $13.00	Medium
5/9/2017	Jefferies Financial Group	Set Price Target	Buy	$26.00 ➝ $14.00	Low
5/9/2017	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $20.00	High
5/9/2017	Cowen	Set Price Target	Outperform	$42.00 ➝ $20.00	Medium
5/9/2017	Mizuho	Downgrade	Buy ➝ Neutral	$22.00 ➝ $10.00	High
5/9/2017	BMO Capital Markets	Reiterated Rating	Buy	$24.00 ➝ $17.00	High
4/12/2017	Jefferies Financial Group	Set Price Target	Buy	$26.00	Low
3/29/2017	BMO Capital Markets	Reiterated Rating	Buy	$24.00	Low
3/24/2017	Piper Jaffray Companies	Lower Price Target	Overweight	$32.00 ➝ $30.00	Low
2/28/2017	Mizuho	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00	N/A
2/28/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$20.00	N/A
2/27/2017	Guggenheim	Initiated Coverage	Buy	$30.00	N/A
2/22/2017	Mizuho	Reiterated Rating	Buy	$25.00	N/A
12/18/2016	Jefferies Financial Group	Set Price Target	Buy	$26.00	N/A
12/16/2016	Mizuho	Upgrade	Neutral ➝ Buy	$14.00 ➝ $25.00	N/A
12/9/2016	Mizuho	Downgrade	Buy ➝ Neutral	$30.00 ➝ $14.00	N/A
12/8/2016	UBS Group	Set Price Target	Buy	$23.00	N/A
12/8/2016	Jefferies Financial Group	Set Price Target	Buy	$26.00	N/A
12/8/2016	BMO Capital Markets	Reiterated Rating	Outperform	$29.00 ➝ $24.00	N/A
12/1/2016	Mizuho	Reiterated Rating	Buy		N/A
11/28/2016	BMO Capital Markets	Reiterated Rating	Outperform	$29.00	N/A
11/28/2016	Citigroup	Upgrade	Neutral ➝ Buy		N/A
11/8/2016	Mizuho	Boost Price Target	Buy	$29.00 ➝ $30.00	N/A
10/31/2016	Mizuho	Lower Price Target	Buy	$33.00 ➝ $29.00	N/A

(Data available from 10/19/2016 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/23/2021

0 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/22/2021

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/22/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/21/2021

1 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/21/2021

2 very positive mentions
3 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

8/20/2021

4 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/19/2021

4 very positive mentions
12 positive mentions
6 negative mentions
3 very negative mentions

Mentions as of

10/19/2021

Current Sentiment

Recent Stories by Sentiment

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Today's Range

Now: $112.76

$112.67

$114.00

50 Day Range

MA: $109.04

$103.19

$114.86

52 Week Range

Now: $112.76

$66.41

$116.66

Volume

16,081 shs

Average Volume

1,551,421 shs

Market Capitalization

$25.47 billion

P/E Ratio

50.12

Dividend Yield

N/A

Beta

1.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Therapeutics Public?: The following Wall Street analysts have issued reports on Horizon Therapeutics Public in the last twelve months: Bank of America Co., BMO Capital Markets, Citigroup Inc., Guggenheim, Jefferies Financial Group Inc., Maxim Group, Morgan Stanley, Stifel Nicolaus, The Goldman Sachs Group, Inc., Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for HZNP.
What is the current price target for Horizon Therapeutics Public?: 9 Wall Street analysts have set twelve-month price targets for Horizon Therapeutics Public in the last year. Their average twelve-month price target is $119.89, suggesting a possible upside of 6.1%. Morgan Stanley has the highest price target set, predicting HZNP will reach $135.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $100.00 for Horizon Therapeutics Public in the next year.
View the latest price targets for HZNP.
What is the current consensus analyst rating for Horizon Therapeutics Public?: Horizon Therapeutics Public currently has 1 sell rating, 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HZNP will outperform the market and that investors should add to their positions of Horizon Therapeutics Public.
View the latest ratings for HZNP.
What other companies compete with Horizon Therapeutics Public?: Other companies that are similar to Horizon Therapeutics Public include Johnson & Johnson, Pfizer, Eli Lilly and, Merck & Co., Inc., AbbVie, Bristol-Myers Squibb, Zoetis, Royalty Pharma, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics, Supernus Pharmaceuticals and Endo International.
How do I contact Horizon Therapeutics Public's investor relations team?: Horizon Therapeutics Public's physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company's listed phone number is (531) 772-2100 and its investor relations email address is [email protected] The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

NASDAQ:HZNP - Horizon Therapeutics Public Stock Price Target and Predictions

Analyst Price Target for HZNP

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.02 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Therapeutics Public?

What is the current price target for Horizon Therapeutics Public?

What is the current consensus analyst rating for Horizon Therapeutics Public?

What other companies compete with Horizon Therapeutics Public?

How do I contact Horizon Therapeutics Public's investor relations team?